Comprehensive Clinical Development
is pleased to announce the expansion of the Company with the relocation to its corporate headquarters in Miramar, Florida.
The new Miramar, Florida, facility will enable further expansion for the Company’s future growth. Comprehensive has also recently expanded its operational capacity in Tacoma, Washington, with 250 beds. This clinic not only increases capacity for clinical conduct, but broadens access to special populations including oncology and the capability to conduct radiolabeled studies.
“Relocating our corporate headquarters represents an investment in our future,” stated Comprehensive CEO
Jack McGovern
. “We are extremely pleased at the rate Comprehensive is succeeding in this difficult economy and the confidence our clients have in Comprehensive. We are committed to continuing our commitment to quality delivery of clinical development services from our new headquarters. This is another step toward extending our clinical research services, therapeutic areas and customer relationships.”
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
FDA Fast Tracks Johnson & Johnson’s Nipocalimab for Fetal Neonatal Alloimmune Thrombocytopenia
March 27th 2024Johnson & Johnson is moving forward with a pair of Phase III trials of nipocalimab to reduce the risk of fetal neonatal alloimmune thrombocytopenia in alloimmunized pregnant patients.